Product image of Magnevist (Gadopentetate Dimeglumine) supplied by GNH India

Magnevist

Active Ingredient:
Gadopentetate Dimeglumine
Origin:
EU

Magnevist (Gadopentetate Dimeglumine)

Gadopentetate dimeglumine, the active ingredient in Magnevist, is a gadolinium-based contrast agent presented as a 0.5 mmol/mL injection solution for intra‑articular use. It enhances magnetic resonance imaging (MRI) signal intensity to aid diagnostic visualization in patients undergoing imaging studies.

GNH India supplies Magnevist as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Bayer Ab

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Magnevist (gadopentetate dimeglumine) is used as a contrast agent in magnetic resonance imaging (MRI) to improve visualization of anatomical structures.

  • Central nervous system imaging: improves detection of lesions, tumors, and vascular abnormalities.
  • Musculoskeletal imaging: enhances visualization of joints, cartilage, and soft‑tissue pathology.
  • Cardiovascular imaging: facilitates assessment of cardiac chambers, vessels, and perfusion.
  • Abdominal and pelvic imaging: aids in delineating liver lesions, tumors, and inflammatory disease.

How It Works

  • Gadopentetate dimeglumine is a paramagnetic gadolinium chelate that shortens the T1 relaxation time of nearby water protons. After intravenous or intra‑articular injection, it distributes in the extracellular space and is cleared renally, producing a temporary increase in signal intensity on T1‑weighted MRI sequences, thereby improving contrast between normal and pathological tissues.

Side Effects

Magnevist may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects

  • Nausea: mild and transient.
  • Headache: occasional during or after injection.
  • Injection site discomfort: mild pain or burning sensation.
  • Warmth or flushing: brief sensation of heat.

Serious or Rare Side Effects

  • Nephrogenic systemic fibrosis: rare fibrotic disorder in patients with severe renal impairment.
  • Severe allergic reaction: anaphylaxis or hypersensitivity requiring immediate medical attention.
  • Acute kidney injury: rapid decline in renal function, particularly in at‑risk patients.
  • Cardiovascular events: hypotension or arrhythmia observed in rare cases.

Precautions & Warnings

Prior to administration, several safety considerations should be observed.

  • Renal function assessment: evaluate kidney function before administration.
  • Pregnancy: use only if benefit outweighs risk (Category C).
  • Hydration: ensure adequate patient hydration to facilitate renal clearance.
  • Allergy history: screen for prior gadolinium or contrast media reactions.
  • Concurrent nephrotoxic drugs: avoid or monitor closely.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Magnevist may interact with other agents affecting renal function or contrast safety.

Major Interactions (Avoid)

  • Severe renal impairment: contraindicated due to risk of nephrogenic systemic fibrosis.
  • High‑dose iodinated contrast within 24 hours: increased risk of renal toxicity.

Moderate Interactions (Monitor Closely)

  • Loop diuretics: may affect renal clearance, monitor kidney function.
  • Nephrotoxic antibiotics (e.g., aminoglycosides): monitor renal function.
  • ACE inhibitors/ARBs: may influence renal perfusion, observe closely.

Frequently Asked Questions

Magnevist is a gadolinium‑based contrast agent used to enhance magnetic resonance imaging (MRI) examinations. By increasing signal intensity on T1‑weighted images, it helps radiologists better visualize normal anatomy and detect abnormalities such as tumors, vascular lesions, and inflammatory conditions.

Gadopentetate dimeglumine contains a paramagnetic gadolinium ion chelated to a carrier molecule. After injection, the chelate shortens the T1 relaxation time of nearby water protons, producing a brighter signal on T1‑weighted MRI sequences and thereby improving contrast between tissues.

The dose of Magnevist is determined by the prescribing physician based on the patient’s weight, the specific imaging study, and renal function. Healthcare professionals calculate the appropriate amount to achieve optimal image quality while minimizing risk.

Magnevist is classified as Pregnancy Category C, indicating that risk to the fetus cannot be ruled out. It should be used only when the potential diagnostic benefit justifies the potential risk. Limited data are available for breastfeeding; clinicians should weigh benefits against possible exposure to the infant.

To order Magnevist, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and any necessary import documentation.

Magnevist (gadopentetate dimeglumine) is a linear gadolinium chelate, whereas agents such as Gadobutrol are macrocyclic and have a higher thermodynamic stability. Linear agents may carry a slightly higher risk of nephrogenic systemic fibrosis in patients with severe renal impairment, but all agents provide comparable image enhancement when used appropriately.

Magnevist should be stored refrigerated at 2–8 °C, protected from light, and must not be frozen or shaken. Keep the vial in its original packaging until use, and discard any solution that appears discolored or contains particles.

Magnevist is supplied as an injectable solution and is administered by a qualified healthcare professional. It is typically injected intravenously, but the product may also be used intra‑articularly for specific imaging protocols, following the prescribed dosage and technique.

The most serious risks include nephrogenic systemic fibrosis (especially in patients with severe renal dysfunction), severe allergic reactions such as anaphylaxis, and acute kidney injury. Prompt recognition and management of these events are essential, and patients at risk should be carefully screened before use.

Magnevist should be avoided in patients with known severe renal impairment (e.g., GFR < 30 mL/min/1.73 m²) due to the risk of nephrogenic systemic fibrosis, and in individuals with a documented hypersensitivity to gadopentetate dimeglumine or any component of the formulation.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Gadopentetate Dimeglumine

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT